Dr. Sharvil Patel, Managing Director of Cadila Healthcare at ZyCov-D, will serve adults as well as adolescents aged 12-18 when approved.

Zydus Cadila said Thursday that he applied Emergency use authorization (EUA) With the Drugs Controller General of India (DCGI) COVID-19 (New Coronavirus Infection) Vaccine ZyCoV-D. According to the company, it will be ready for deployment within 45 to 60 days of approval.

ZyCoV-D is advertised as the first plasmid DNA vaccine COVID-19 (New Coronavirus Infection) It is also of increasing interest because it can be administered with a needleless applicator.

Companies that already have anti-COVID treatments available on the market claim to have conducted the largest clinical trials in India to date at more than 50 centers, including people between the ages of 12 and 18. It was.

How is it different from other vaccines?

  • ZyCoV-D 3 dose vaccine, Unlike Bharat Biotech’s Covaxin and Serum Institute of India-manufactured Covishield jab.

But the company said it has We also evaluated a two-dose regimen For the ZyCoV-D vaccine using a dose of 3 milligrams per visit, the immunogenicity results are Found to be equivalent to the current 3-dose regimen..

This will further help shorten the overall course of vaccination while maintaining a high safety profile for the vaccine in the future, the company added.

  • ZyCoV-D is advertised as’Needle-free vaccine..

that is Intradermal vaccine, Applied using the PharmaJet Needle Free System. Needleless syringes use a narrow fluid stream to deliver the vaccine to penetrate the skin and deliver the vaccine to the appropriate tissue depth. According to the company, this methodology eliminates the possibility of needlestick injuries and also leads to a significant reduction in all types of side effects. It also helps people suffering from tripanophobia, a common condition characterized by irrational fear of blood and needles. Fear of needles is estimated to affect up to 25 percent of adults.

  • ZyCoV-D Not very sensitive to temperature Different from competitors. The specified storage temperature is 2-8 ° C, but it shows good stability even at a temperature of 25 ° C for at least 3 months.

The· Thermal stability The use of vaccines facilitates the transportation and storage of vaccines and helps alleviate the problem of cold chain failure that leads to waste of vaccines.

  • The plasmid DNA platform facilitates production with minimal biosafety requirements.

Manufactured in a BSL-1 grade lab, manufacturing costs are reduced and production unit expansion costs are guaranteed. In comparison, covaxin requires a biosafety level 3 lab to produce jabs.

  • The plasmid DNA platform also allows it to be produced A new construct to deal with mutations In the virus Things that have already occurred, etc.

Who will benefit?

Dr. Sharvil Patel, Managing Director of Cadila Healthcare, mentioned the vaccine when it was approved. Useful not only for adults but also for adolescents aged 12-18 Age group.

Science Behind the Jab: How Does It Work?

ZyCoV-D is a plasmid DNA vaccine that, when injected, produces the SARS-CoV-2 virus peplomer, which elicits an immune response mediated by the cellular and humoral arms of the human immune system. It plays an important role in protecting against illness. Not only virus clearance.

Simply put, vaccines are made by making a close enough copy of the viral DNA sequence to cause no harm or illness, but the next time the body encounters the actual virus, the immune system reacts. Will be triggered.

Results of provisional effectiveness

The vaccine showed a primary efficacy of 66.6 percent in symptomatological RT-PCR positive cases in an interim analysis.On the other hand, there are no medium cases COVID-19 (New Coronavirus Infection) Disease was observed in the vaccine group after the third dose, suggesting 100% efficacy for moderate disease.

No serious cases or deaths COVID-19 (New Coronavirus Infection) It occurred in the vaccine group after the second dose of the vaccine.

However, Phase 3 study data has not yet been peer reviewed.

Vaccine makers also claimed that vaccine efficacy data was collected through India’s largest clinical trial. Coronavirus Vaccines so far.Studies conducted at the peak of the second wave at more than 50 clinical sites nationwide COVID-19 (New Coronavirus Infection) Dr. Patel, managing director of Cadilla Healthcare, said he reaffirmed the effectiveness of the vaccine against new mutants, especially the delta mutant.

He also emphasized that the plasmid DNA platform is ideally suitable for coping. COVID-19 (New Coronavirus Infection) It can be easily adapted to deal with viral mutations. In addition, DNA vaccines offer many potential advantages over traditional approaches involving stimulation of both B-cell and T-cell responses, improving vaccine stability, WHO said.

Availability and price

The company plans to manufacture doses of 10-12 chlores annually after obtaining an emergency use authorization. However, the company gave no hint as to the expected price of vaccine jabs. Vaccine prices are billed separately and needleless applicators are clarified to be costly. However, the company has not yet decided whether to adjust the prices of jabs and applicators to roll out the final product.

“It’s too early to comment on the price. The discussion hasn’t happened yet. We’ll announce the price before the commercial launch of the ZyCoV-D,” Patel said in a press conference. He said that up to 500 rupees have been invested in the development of the Zydus vaccine so far.

Zydus Cadila’s needle-free, plasmid DNA COVID vaccine; all you need to know Source link Zydus Cadila’s needle-free, plasmid DNA COVID vaccine; all you need to know

Source link